Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascentage Pharma Group International (AAPG) Other Accumulated Expenses (2023 - 2025)

Ascentage Pharma Group International posted quarterly Other Accumulated Expenses of $39.0 million for Q4 2025, up 8.56% year-on-year from $35.9 million in Q4 2024, and up 12.07% on a QoQ basis from $34.8 million in Q2 2025.

Ascentage Pharma Group International (AAPG) has 3 years of Other Accumulated Expenses data on file, last reported at $39.0 million in Q4 2025.

  • For the quarter ending Q4 2025, Other Accumulated Expenses rose 8.56% year-over-year to $39.0 million; the trailing twelve-month figure through Dec 2025 stood at $39.0 million (up 8.56% YoY), and the FY2025 full-year result was $39.6 million, up 11.89% from the prior year.
  • Other Accumulated Expenses for Q4 2025 stood at $39.0 million, up from $34.8 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $39.0 million in Q4 2025 and bottomed at $28.7 million in Q4 2023.
  • The 3-year median for Other Accumulated Expenses is $35.4 million (2024), against an average of $34.6 million.
  • The widest annual swing landed in 2024, when Other Accumulated Expenses climbed 25.03%; it then advanced 8.56% in 2025.
  • A 3-year view of Other Accumulated Expenses shows it stood at $28.7 million in 2023, then advanced by 25.03% to $35.9 million in 2024, then advanced by 8.56% to $39.0 million in 2025.
  • The last three Other Accumulated Expenses figures came in at $39.0 million (Q4 2025), $34.8 million (Q2 2025), and $35.9 million (Q4 2024), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Quantum Biopharma 1,638,563.89 Bn 1,638,563.89 Bn -
2 Alterity Therapeutics 767,934.24 Bn 767,934.20 Bn -
3 Legend Biotech 2,937.00 Bn 2,936.10 Bn 242.10 Mn
4 Nanobiotix 2,282.79 Bn 2,282.72 Bn -
5 Akari Therapeutics 2,169.69 Bn 2,169.69 Bn -
6 Vertex Pharmaceuticals 110.41 Bn 103.16 Bn 2.59 Bn
7 Regeneron Pharmaceuticals 66.44 Bn 57.69 Bn 3.31 Bn
8 Evaxion A 65.44 Bn 65.42 Bn -
9 Alnylam Pharmaceuticals 39.53 Bn 36.52 Bn 959.66 Mn
10 Ascentage Pharma Group International 1.11 Bn 937.28 Mn -

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 39.01 Mn
Jun 30, 2025 34.81 Mn
Dec 31, 2024 35.93 Mn
Dec 31, 2023 28.74 Mn